Stock Track | iRadimed Plummets 7.77% Intraday Despite Q1 Earnings Beat on Guidance Concerns

Stock Track05-01

iRadimed Corporation's stock plummeted 7.77% during intraday trading on Friday, a sharp decline following the release of the company's first-quarter financial results.

The medical device maker reported Q1 non-GAAP earnings of $0.49 per share, beating analyst estimates of $0.45, while revenue of $22 million also exceeded expectations. However, the company's guidance for the second quarter appears to have disappointed investors. iRadimed expects Q2 revenue in the range of $20 million to $21 million, which suggests a potential sequential decline from the strong Q1 figure.

While the company reaffirmed its full-year 2026 outlook and highlighted strong early order activity for its newly launched next-generation MRI-compatible IV infusion pump, the market's reaction indicates concerns over the near-term revenue trajectory and the pace of the new product's contribution to growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161498938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161498938","market":"hk","top_or_hot":-1,"title":"Stock Track | iRadimed Plummets 7.77% Intraday Despite Q1 Earnings Beat on Guidance Concerns","media":"Stock Track","content":"<p>iRadimed Corporation's stock plummeted 7.77% during intraday trading on Friday, a sharp decline following the release of the company's first-quarter financial results.</p><p>The medical device maker reported Q1 non-GAAP earnings of $0.49 per share, beating analyst estimates of $0.45, while revenue of $22 million also exceeded expectations. However, the company's guidance for the second quarter appears to have disappointed investors. iRadimed expects Q2 revenue in the range of $20 million to $21 million, which suggests a potential sequential decline from the strong Q1 figure.</p><p>While the company reaffirmed its full-year 2026 outlook and highlighted strong early order activity for its newly launched next-generation MRI-compatible IV infusion pump, the market's reaction indicates concerns over the near-term revenue trajectory and the pace of the new product's contribution to growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | iRadimed Plummets 7.77% Intraday Despite Q1 Earnings Beat on Guidance Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | iRadimed Plummets 7.77% Intraday Despite Q1 Earnings Beat on Guidance Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-01 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>iRadimed Corporation's stock plummeted 7.77% during intraday trading on Friday, a sharp decline following the release of the company's first-quarter financial results.</p><p>The medical device maker reported Q1 non-GAAP earnings of $0.49 per share, beating analyst estimates of $0.45, while revenue of $22 million also exceeded expectations. However, the company's guidance for the second quarter appears to have disappointed investors. iRadimed expects Q2 revenue in the range of $20 million to $21 million, which suggests a potential sequential decline from the strong Q1 figure.</p><p>While the company reaffirmed its full-year 2026 outlook and highlighted strong early order activity for its newly launched next-generation MRI-compatible IV infusion pump, the market's reaction indicates concerns over the near-term revenue trajectory and the pace of the new product's contribution to growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRMD","symbol_name":"iRadimed Corporation","start_time":0,"source_url":"","article_id":"1161498938","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161498938","pubTimestamp":1777644341,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"iRadimed Corporation's stock plummeted 7.77% during intraday trading on Friday, a sharp decline following the release of the company's first-quarter financial results.The medical device maker...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRMD":"iRadimed Corporation"},"translate_title":"个股追踪|iRadimed盘中暴跌7.77%尽管Q1盈利超指引担忧","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRMD":1},"content_text":"iRadimed Corporation's stock plummeted 7.77% during intraday trading on Friday, a sharp decline following the release of the company's first-quarter financial results.The medical device maker reported Q1 non-GAAP earnings of $0.49 per share, beating analyst estimates of $0.45, while revenue of $22 million also exceeded expectations. However, the company's guidance for the second quarter appears to have disappointed investors. iRadimed expects Q2 revenue in the range of $20 million to $21 million, which suggests a potential sequential decline from the strong Q1 figure.While the company reaffirmed its full-year 2026 outlook and highlighted strong early order activity for its newly launched next-generation MRI-compatible IV infusion pump, the market's reaction indicates concerns over the near-term revenue trajectory and the pace of the new product's contribution to growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161498938","isCrawlerRequest":true}